Aatorvastatin effect on lung function and serum level of hs-CRP in chemical warfare patients with obstructive pulmonary disease.
Not Applicable
- Conditions
- Chronic obstructive pulmonary disease.Chronic lower respiratory diseases(J00-J99)
- Registration Number
- IRCT201101095579N1
- Lead Sponsor
- Ardabil University Of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
Chemical warfare victims with obstructive pulmonary disease; age between 35-85; clinically stable disease in previous 8 weeks; acceptance of study design by patients.
Exclusion criteria: Active infectious disease; bronchiectasis; chronic inflammatory diseases; soft tissue diseases; active liver and kidney diseases; cancer; cardiac disease (myocardial infarction and unstable angina in previous 6 months); sensitivity to atorvastatin; myopathy; myositis; hypercholestrolemia history; history of atorvastatin consumption; history of smoking; asthma; elevated CPK and elevated liver function test more than twice.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method COPD Assessment Test (CAT) questionnaire. Timepoint: At the beginning of study and 9 weeks after intervention. Method of measurement: CAT questionnaire score (score from 0 to 40).;Six Minute Walk Distance Test (6MWDT). Timepoint: At the beginning of study, 4 weeks and 9 weeks after intervention. Method of measurement: Distance walked in six minute (Meter).;Pulmonary volumes. Timepoint: At the beginning of study, 4 weeks and 9 weeks after intervention. Method of measurement: Spirometry.;The level of hs-CRP. Timepoint: At the beginnig of study and 9 weeks after intervention. Method of measurement: Laboratory.;St. George Respiratory Questionnaire. Timepoint: At the beginning of study and 9 weeks after intervention. Method of measurement: The questionnaire of assessing symptoms score, activity score, impact score and total score.
- Secondary Outcome Measures
Name Time Method O2 saturation of arterial blood. Timepoint: At the beginning of study, 4 weeks and 9 weeks after intervention. Method of measurement: Pulse oximetry device.;Atorvastatin side effects. Timepoint: 4 weeks and 9 weeks after intervention. Method of measurement: According to patient symptoms.